Molecular dissection of bile duct cancer reveals subtypes with different origins and varying potential treatments

December 13, 2017, Agency for Science, Technology and Research (A*STAR), Singapore

Researchers have discovered that cholangiocarcinoma (CCA), a form of liver cancer also known as bile duct cancer, consists of several molecular subtypes with distinct potential therapies and prognoses.

An international collaboration led by Patrick Tan of A*STAR's Biomedical Research Council, analyzed tumors collected from almost 500 patients in 10 countries, in a study that is part of the International Cancer Genome Consortium. By examining a large, diverse group, the researchers were able to uncover patterns missed in earlier investigations, such as one that included only North American patients, all of whom were free of the liver-fluke infection that is a common catalyst for bile duct cancer in Southeast Asian patients.

Using modern high-throughput DNA sequencing, the team investigated the genomic sequences of the tumors and their epigenomic and gene expression profiles. They divided the cancers into four groups with different patterns of mutations and other genetic defects, two of which were associated with liver-fluke infection. "The current way of classifying CCAs is by their anatomical subtype. Our data shows that if you look at molecular data, you get more clinically relevant subtypes that have different potential therapies and prognoses," says Bin Tean Teh of the National Cancer Centre Singapore, one of the study's senior authors.

One of the clusters was characterized by changes in genes associated with immune response, suggesting that it might be a candidate for immunotherapy treatment. Likewise, the characteristics of some of the tumors indicated that they might respond to therapeutic interventions currently in use or under development. "We've shown that about a third of the patients can be treated using existing therapies, if experimental drugs were included it would be even more", says lead author, Apinya Jusakul. Currently, surgery is the only treatment for cancer.

The molecular clusters can also guide researchers in understanding the development of CCA. Two of the clusters had an excess of methylation, a DNA modification. Differences in the methylation patterns offer clues about the processes acting in each cluster. "Based on molecular data, we can speculate about the different mechanisms leading to different DNA changes in the development of CCA. You really can't see that from just the anatomical information," says co-lead author Chern Han Yong.

These findings demonstrate that distinct can result from different triggers. Learning more about these subtypes and how they link with various carcinogenic processes may reveal the mechanisms behind these cancers and guide the development of therapeutic interventions.

Explore further: Discovering potential targeted treatments for bile duct cancer

More information: Apinya Jusakul et al. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma, Cancer Discovery (2017). DOI: 10.1158/2159-8290.CD-17-0368

Related Stories

Discovering potential targeted treatments for bile duct cancer

August 4, 2017
An international study on bile duct cancer or cholangiocarcinoma (CCA), a rare but highly lethal form of liver cancer, has discovered that tumours in the bile duct may be made up of different cancer subtypes. This finding ...

Regular aspirin use may protect against bile duct cancer

May 9, 2016
(HealthDay)—Regular aspirin use may lower the risk of bile duct cancer, according to a study published online April 26 in Hepatology.

Drug improves survival of patients with rare cancer by almost a quarter

May 18, 2017
Patients who take capecitabine after surgery for bile duct cancer live for almost a year and a half longer than those not given the drug, according to the results of a Cancer Research UK funded trial presented at the 2017 ...

Bile duct cancer study may pave way for new treatments

February 17, 2015
Patients with bile duct cancer could be helped by a new class of experimental drug, a study has shown.

Bile protein may help detect pancreatic cancer

October 14, 2013
(HealthDay)—A protein "biomarker" in bile correctly identifies pancreatic cancer and may detect the cancer earlier than some markers in blood, according to a new study.

Bile duct cancer study sheds light on triggers that cause disease

October 10, 2016
Scientists have identified a molecule that drives the development of bile duct cancer.

Recommended for you

Do prostate cancer cells have an Achilles' heel?

April 25, 2018
Researchers at the University of Illinois at Chicago describe new ways to selectively kill prostate cancer cells by exploiting the cells' revved-up metabolism. They report their findings in the online journal, eLife.

New breath and urine tests detect early breast cancer more accurately

April 25, 2018
A new method for early and accurate breast cancer screening has been developed by researchers at Ben-Gurion University of the Negev and Soroka University Medical Center, using commercially available technology.

Research shows possible new target for immunotherapy for solid tumors

April 24, 2018
Research from the University of Cincinnati (UC) reveals a potential new target to help T cells (white blood cells) infiltrate certain solid tumors.

Changes in breast tissue increase cancer risk for older women

April 24, 2018
Researchers in Norway, Switzerland, and the United States have identified age-related differences in breast tissue that contribute to older women's increased risk of developing breast cancer. The findings, published April ...

Targeting molecules called miR-200s and ADAR2 could prevent tumor metastasis in patients with colorectal cancer

April 24, 2018
Colorectal cancer is the third most common cancer worldwide and the third-leading cause of cancer-related deaths. The main cause of death in patients with colorectal cancer is liver metastasis, with nearly 70% of patients ...

Experimental arthritis drug prevents stem cell transplant complication

April 24, 2018
An investigational drug in clinical trials for rheumatoid arthritis prevents a common, life-threatening side effect of stem cell transplants, new research from Washington University School of Medicine in St. Louis shows. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.